Topic Review
Oligodendroglial Cells
Oligodendrocytes (OLs) are ramified glial cells within the central nervous system (CNS) whose terminal processes generate myelin and enwrap neuronal axons. 
  • 785
  • 04 Aug 2021
Topic Review
Opioid Analgesia and Opioid-Induced Adverse Effects
Opioids are broadly used as therapeutic agents against moderate to severe acute and chronic pain. Noticeably, these analgesics have many limitations as they induce analgesic tolerance, addiction, physical dependence, respiratory depression, and various other behavioural adverse effects that often result in patient non-compliance. In addition, the actual mechanisms of opioid-induced adverse reactions over long-term use are not entirely understood. 
  • 539
  • 08 Dec 2021
Topic Review
Opioid-Induced Constipation in Cancer Patients
Opioid-induced constipation (OIC) is a disabling symptom which 60–90 percent of cancer patients with chronic opioid use experience. Peripherally acting μ-opioid receptor antagonists (PAMORAs) are a class of medications aiming to reverse opioids’ adverse effects on the gut by interacting with opioid receptors in the gastrointestinal tract without significantly crossing the blood–brain barrier, and therefore they are not affecting the analgesic opioid effects in the central nervous system.
  • 116
  • 22 Mar 2024
Topic Review
Oral Administration for Small Extracellular Vesicles Delivery
Small extracellular vesicles (sEVs) have burst into biomedicine as a natural therapeutic alternative for different diseases. Considered nanocarriers of biological origin, various studies have demonstrated the feasibility of their systemic administration, even with repeated doses. sEVs can resist the degradative conditions of the gastrointestinal tract after oral administration, accumulating regionally in the intestine, where they are absorbed for systemic biodistribution. 
  • 508
  • 14 Mar 2023
Topic Review
Oral Bioavailability and Regulatory Aspects
Oral bioavailability refers to the extent a substance or drug becomes completely available to systemic circulation or to its intended biological destination(s) via the oral route. High oral bioavailability reduces the amount of a drug necessary to achieve a desired pharmacological effect, therefore reducing the risk of side-effects and toxicity. Low oral bioavailability results in low efficacy and is a major reason for drug candidates failing to reach the market. Hence, oral bioavailability is one of the most important properties in drug design and development.
  • 551
  • 11 Oct 2021
Topic Review
Oral Microbiome Related Diseases
The human oral microbiome refers to an ecological community of symbiotic and pathogenic microorganisms found in the oral cavity. The oral cavity is an environment that provides various biological niches, such as the teeth, tongue, and oral mucosa. The oral cavity is the gateway between the external environment and the human body, maintaining oral homeostasis, protecting the mouth, and preventing disease.
  • 682
  • 26 Jul 2021
Topic Review
Oral siRNA Delivery for Inflammatory Bowel Disease Treatments
RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Oral nanomedicines carrying small interfering RNA (siRNA) drugs include the following two: (1) Polyplex or lipoplex. (2) Polyplex or lipoplex embedded in hydrogels or polymeric materials
  • 547
  • 11 Oct 2022
Topic Review
Oral subunit vaccine design
Many pathogens invade the host at the intestinal surface. To protect against these enteropatho-gens, the induction of intestinal secretory IgA (SIgA) responses is paramount. While systemic vaccination provides strong systemic immune responses, oral vaccination is the most efficient way to trigger protective SIgA responses. However, the development of oral vaccines, especially oral subunit vaccines, is challenging due to mechanisms inherent to the gut. Oral vaccines need to survive the harsh environment in the gastrointestinal tract, characterized by low pH and intestinal proteases and need to reach the gut-associated lymphoid tissues, which are protected by chemical and physical barriers that prevent efficient uptake. Furthermore, they need to surmount default tolerogenic responses present in the gut, resulting in suppression of immunity or tolerance. Several strategies have been developed to tackle these hurdles, such as delivery systems that protect vaccine antigens from degradation, strong mucosal adjuvants that induce robust immune responses and targeting approaches that aim to selectively deliver vaccine antigens towards specific immune cell populations.
  • 524
  • 12 Jan 2021
Topic Review
Organic Cation Transporters in Lung
Organic cation transporters (OCT) 1, 2 and 3 and novel organic cation transporters (OCTN) 1 and 2 of the solute carrier 22 (SLC22) family are involved in the cellular transport of endogenous compounds such as neurotransmitters, l-carnitine and ergothioneine. OCT/Ns have also been implicated in the transport of xenobiotics across various biological barriers, for example biguanides and histamine receptor antagonists. In addition, several drugs used in the treatment of respiratory disorders are cations at physiological pH and potential substrates of OCT/Ns. OCT/Ns may also be associated with the development of chronic lung diseases such as allergic asthma and chronic obstructive pulmonary disease (COPD) and, thus, are possible new drug targets.
  • 754
  • 23 Jan 2021
Topic Review
Organic Germanium Compounds
Germanium is an essential microelement, and its deficiency can result in numerous diseases, particularly oncogenic conditions. Consequently, water-soluble germanium compounds, including inorganic and coordination compounds, have attracted significant attention due to their biological activity. 
  • 542
  • 01 Jun 2023
  • Page
  • of
  • 106
Video Production Service